文献速递泌尿男性生殖肿瘤支持与姑息治疗

进行性转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617治疗的健康相关生活质量、疼痛与症状性骨骼事件(PSMAfore):一项开放标签随机3期试验

Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-05-26

PSMAfore研究在74个中心、14个国家纳入468例紫杉烷未治、PSMA阳性转移性去势抵抗性前列腺癌患者,按1:1随机接受[177Lu]Lu-PSMA-617或更换雄激素受体通路抑制剂(ARPI)。与更换ARPI相比,[177Lu]Lu-PSMA-617延迟了所有评估的FACT-P、EQ-5D-5L和BPI-SF量表及子量表的恶化时间,并延迟了首次症状性骨骼事件。

要点

  • FACT-P总分恶化中位时间:[177Lu]Lu-PSMA-617组7.46个月 vs 更换ARPI组4.27个月(HR 0.61,95%CI 0.50-0.75)
  • EQ-5D-5L效用评分恶化中位时间:6.28个月 vs 3.88个月(HR 0.67,95%CI 0.54-0.82)
  • BPI-SF疼痛强度恶化中位时间:5.03个月 vs 3.65个月(HR 0.72,95%CI 0.59-0.88)

核心结论

  • [177Lu]Lu-PSMA-617可能延迟患者报告结局的恶化并预防症状性骨骼事件,对照为更换ARPI,人群为PSMA阳性、既往一种ARPI治疗后进展一次的紫杉烷未治转移性去势抵抗性前列腺癌患者。

研究设计与样本

  • PSMAfore为开放标签、随机、3期试验,在14个国家的74个研究者中心开展。
  • 纳入标准:转移性去势抵抗性前列腺癌、既往一种ARPI治疗后进展一次且为更换ARPI的候选者、经镓-68[68Ga]Ga-PSMA-11 PET-CT确认至少一个PSMA阳性且无排除性PSMA阴性转移灶、年龄18岁及以上、ECOG体能状态0-1。
  • 共468例患者按1:1随机分配至[177Lu]Lu-PSMA-617组(n=234)或更换ARPI组(n=234)。
  • [177Lu]Lu-PSMA-617给药方案为7.4 GBq,每6周一次,共6个周期;更换ARPI为口服阿比特龙或恩扎卢胺,按当地标签。
  • 主要终点为影像学无进展生存期;本次分析为总生存期第三次 interim 分析,数据截止日期为2024年2月27日。

主要发现

  • FACT-P总分恶化中位时间:[177Lu]Lu-PSMA-617组7.46个月(95%CI 6.08-8.54) vs 更换ARPI组4.27个月(95%CI 3.45-4.50),HR 0.61(95%CI 0.50-0.75)。
  • EQ-5D-5L效用评分恶化中位时间:[177Lu]Lu-PSMA-617组6.28个月(95%CI 4.70-7.89) vs 更换ARPI组3.88个月(95%CI 3.25-4.44),HR 0.67(95%CI 0.54-0.82)。
  • BPI-SF疼痛强度恶化中位时间:[177Lu]Lu-PSMA-617组5.03个月(95%CI 4.40-6.80) vs 更换ARPI组3.65个月(95%CI 3.09-4.37),HR 0.72(95%CI 0.59-0.88)。
  • 首次症状性骨骼事件中位时间:[177Lu]Lu-PSMA-617组未达到(95%CI NE-NE) vs 更换ARPI组17.97个月(95%CI 14.26-NE),HR 0.41(95%CI 0.26-0.63)。
  • 最常见≥3级治疗中出现的不良事件为贫血:[177Lu]Lu-PSMA-617组227例中14例(6%) vs 更换ARPI组232例中16例(7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the PSMAfore study, lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) significantly improved radiographic progression-free survival compared with change of androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. Here, we present in-depth analyses of time to worsening of health-related quality of life (HRQOL) and pain, and time to first symptomatic skeletal events. METHODS: PSMAfore, an open-label, randomised, phase 3 trial, was conducted at 74 investigator sites (including hospitals with nuclear medicine departments and the research facilities where patients were recruited) across 14 countries. Eligible patients had metastatic castration-resistant prostate cancer, were candidates for ARPI change after one progression on a previous ARPI, had at least one PSMA-positive and no exclusionary PSMA-negative metastatic lesions by gallium-68 [68Ga]Ga-PSMA-11 PET-CT, were aged 18 years or older, and had an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) to [177Lu]Lu-PSMA-617 (7·4 GBq; every 6 weeks for six cycles) or ARPI change (oral abiraterone or enzalutamide per local labelling). The primary endpoint was radiographic progression-free survival. Secondary endpoints included time to worsening in self-reported HRQOL (assessed using the Functional Assessment of Cancer Therapy-Prostate [FACT-P] and EQ-5D-5L) and pain (assessed using the Brief Pain Inventory-Short Form [BPI-SF]) and time to the first symptomatic skeletal event. All analyses were done using the intention-to-treat principle. The study met the primary endpoint of radiographic progression-free survival (reported previously), and overall survival follow-up is ongoing; present analyses are from the third interim analysis of overall survival. This trial is registered with ClinicalTrials.gov, NCT04689828. FINDINGS: Between June 15, 2021, and Oct 7, 2022, 468 patients (426 [91%] were White and 12 [3%] were Black or African American) were randomly assigned to [177Lu]Lu-PSMA-617 (n=234) or ARPI change (n=234). Median follow-up time from randomisation to the third interim analysis data cutoff date (Feb 27, 2024) was 24·11 months (IQR 20·24-27·60) in the [177Lu]Lu-PSMA-617 group and 24·13 months (20·24-27·37) in the ARPI change group. [177Lu]Lu-PSMA-617 delayed time to worsening in all assessed FACT-P, EQ-5D-5L, and BPI-SF scales and subscales versus ARPI change. In the [177Lu]Lu-PSMA-617 versus ARPI change groups, median time to worsening in FACT-P total score was 7·46 months (95% CI 6·08-8·54) versus 4·27 months (3·45-4·50; hazard ratio [HR] 0·61 [95% CI 0·50-0·75]), in EQ-5D-5L utility score was 6·28 months (4·70-7·89) versus 3·88 months (3·25-4·44; 0·67 [0·54-0·82]), and in BPI-SF pain intensity was 5·03 months (4·40-6·80) versus 3·65 months (3·09-4·37; 0·72 [0·59-0·88]). [177Lu]Lu-PSMA-617 also delayed symptomatic skeletal events versus ARPI change: median time to first symptomatic skeletal event was not reached (95% CI not estimable [NE]-NE) in the [177Lu]Lu-PSMA-617 group versus 17·97 months (14·26-NE) in the ARPI change group (HR 0·41 [0·26-0·63]). The most common grade 3 or worse treatment-emergent adverse event was anaemia (14 [6%] of 227 patients in the [177Lu]Lu-PSMA-617 group vs 16 [7%] of 232 patients in the ARPI change group). There were no treatment-related deaths in the [177Lu]Lu-PSMA-617 group and one in the ARPI change group (cerebrovascular accident). INTERPRETATION: [177Lu]Lu-PSMA-617 might delay worsening of patient-reported outcomes and prevent symptomatic skeletal events versus ARPI change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer whose disease has progressed once on a previous ARPI. FUNDING: Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Morris MJ, Shore ND, et al. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol. 2025. PMID: 40441170. doi:10.1016/S1470-2045(25)00189-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。